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ABSTRACT
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
botulinum toxin injection is effective in reducing pain in patients diagnosed with plantar fasciitis.
STUDY DESIGN:  Review of three randomized controlled trials (RCTs) comparing the efficacy 
of botulinum toxin injections versus corticosteroid injections for improving pain and dysfunction
in those diagnosed with plantar fasciitis.
DATA SOURCES:  All articles were presented in English and were taken from peer reviewed 
sources using PubMed. All articles were published from 2012-2017.
OUTCOMES:  Outcomes of investigation measured are pain score measured using the VAS-
visual analog scale and Foot Health Status Questionnaire.
RESULTS:  Ahmad et al. found significant improvement in subjective pain scores following the 
administration of botulinum toxin injected into the plantar fascia after a period of six months and
one year when compared to a placebo of saline. Diaz-Llopis et al. found significant improvement
in subjective pain scores following the administration of botulinum toxin injected into the plantar
fascia after a period of six months when compared to a corticosteroid. Elizondo-Rodriguez et al. 
found significant improvement in subjective pain scores following the administration of 
botulinum toxin injected into the plantar fascia after a period of six months when compared to a 
corticosteroid.
CONCLUSIONS:  These three studies showed a significant improvement in subjective pain 
scores after a minimum period of six months and formalized physical therapy program. The 
efficacy of botulinum toxin in the treatment of plantar fasciitis is apparent but more research is 
needed with larger sample sizes to solidify the hypothesis that botulinum toxin injection should 
be an accepted treatment option across the industry.
KEYWORDS:   plantar fasciitis, botulinum, and injection  
Fry, Botox for Plantar Fasciits 3
INTRODUCTION:
Plantar fasciitis is the most frequent cause of chronic heel pain which generally presents 
in patients who are 40 years of age or older, overweight, sedentary, or engage in intense physical 
activity. The plantar fascia functions to prevent foot collapse because of its tensile strength and 
anatomic orientation. The inflammation of this structure leads to the symptoms experienced by 
approximately 10% of the population.1 Plantar fasciitis is a clinical condition that presents as 
sharp pain in the heel that spans from the medial border of the plantar fascia to its insertion at the
medial tuberosity of the calcaneus. Pain is provoked with loading and with the initial few steps 
following periods of inactivity. These symptoms are elicited by actions such as rising from sleep 
in the morning and toward the end of day at rest. Development of plantar fasciitis is thought to 
be caused by biomechanical defects such as hyper-pronation. Hyper-pronation contributes to the 
excessive mobility of the foot which can increase stress on the plantar fascia.  
Treatment options for plantar fasciitis include operative and non-operative. Operative 
options include plantar fascial debridement and release.2 Non-operative options include physical 
therapy, injections, and insoles.1 Injection options were initially restricted to corticosteroid 
injection which have only limited effectiveness but was the mainstay of treatment due to a lack 
of alternatives.3 An alternative has been proposed for the management of plantar fasciitis which 
is botulinum toxin injections.3,4,5 Botulinum toxin blocks presynaptic acetylcholine reuptake, 
produces weakness of the muscles related to the plantar fascia and reduces the tension which 
improves the pain.5 This is similar to botulinum toxin’s action in the treatment of myofascial 
pain disorders.5 It also has an analgesic action due to the inhibition of the release of 
neurotransmitters involved in nociceptive neural pathways (glutamate, substance P and 
calcitonin-gene related peptide).4 Many practitioners have utilized this therapeutic measure after 
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all other options have been exhausted in the progression of the patient’s case. Therefore, these 
patients may have responded favorably to this therapeutic injection without having to endure the 
other more drastic and painful measures if botulinum toxin was an accepted first line therapy.  
OBJECTIVE:
The objective of this selective EBM review is to determine whether or not botulinum 
toxin injection is effective in reducing pain in patients diagnosed with plantar fasciitis.
METHODS: 
Three randomized controlled trials were chosen for review. The patient population 
selected for review were ambulatory patients above the age of 18 years old with a diagnosis of 
plantar fasciitis. Interventions utilized included injecting botulinum toxin at 100 units into the 
inflamed plantar fascia. Depending on the study, subjects either received the botulinum toxin 
injection, a corticosteroid injection or a saline placebo. The outcomes were patient oriented and 
focused on subjective pain scores utilizing the VAS-visual analog scale or the foot health status 
questionnaire depending on the study. 
The PubMed database was utilized to select the studies. Keywords to search were 
“plantar”, “fasciitis”, “botulinum”, and “injection.” The three studies selected were published in 
peer reviewed journals from 2012-2017 and all were written in English. The inclusion and 
exclusion criteria for all three studies were similar. The inclusion criteria was randomized, 
controlled, blinded study that evaluated subjects aged >18 years of age, ambulatory, and 
diagnosed with plantar fasciitis. The exclusion criteria was patients diagnosed with other 
pathology than plantar fasciitis for heel pain. Detailed inclusion, exclusion criteria, and other 
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individual study characteristics are provided in Table 1. The statistics reported in the studies and 
utilized for the review were mean changes from baseline and p-values. 
Table 1: Demographics & Characteristics of Ahmad et al., Diaz-Llopis et al., & Elizondo-
Rodriguez et al. 
Study Type # Pts Age 
(yrs)
Inclusion Criteria Exclusion Criteria W/D Interventions
Ahmad 
(2017)
RCT 50 31-69 Acute or chronic 
plantar fasciitis 
who had no 
improvement in 
symptoms after a 
minimum of 6 
weeks of non-
operative 
treatment 
Prior botulinum toxin
injections for plantar 
fasciitis 
0 A 1 mL injection of 
100U of IBTA vs. a 
saline placebo 
injection
Diaz 
(2012)
RCT 56 SD 
51-56
Clinical diagnosis
of plantar fasciitis
based on 
presence of heel 
pain during first 
steps after a 
period of rest or 
pain exacerbated 
by walking or by 
standing for 
many hours
Those with heel pain 
due to other causes 
or painful disorders 
of the foot that could 
coexist with plantar 
fasciitis.
0 100U of botulinum 
toxin type A was 
diluted in 1 mL of 
normal saline and 
70U were injected vs. 
2 mL of 
betamethasone 
6mg/mL plus 0.5 mL 
of 1% mepivacaine 
Rodriguez
(2013)
Double
Blind 
RCT
40 29-54 Skeletally mature
with heel pain at 
the insertion of 
the plantar fascia 
or anteromedial 
tuberosity of the 
calcaneus; failure
of conservative 
treatment for 3 
months, which 
consisted of pads 
in ordinary shoe 
and NSAIDs
Previous injections, 
associated 
pathologies or a 
history of infection at
the injection site in 
the previous 3 
months
4 100U of BTX-A was 
injected into each 
muscle belly vs. a 
combination of 2% 
lidocaine and 8mg of 
dexamethasone 
injected into medial 
aspect of the plantar 
surface
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OUTCOMES MEASURED:
This review examined subjective pain scores after therapeutic injections were 
administered. Patients were evaluated over 6 month periods to assess response to the injections. 
To measure the subjective pain responses, two subjective scoring evaluators were utilized; the 
VAS-visual analog scale and the Foot Health Questionnaire. These subjective scoring systems 
evaluated the patients’ response to the injections by their pain with various modalities following 
a designated time period.  
RESULTS:
Ahmad et. al., conducted a randomized, double blinded, placebo controlled trial 
comparing 50 subjects who presented with a diagnosis of plantar fasciitis. The authors reported a
mean age of 51.3 in the placebo group and 48.6 in the botulinum toxin group respectively.2 This 
study included subjects with either acute or chronic plantar fasciitis who had no improvement in 
symptoms after a minimum of 6 weeks of non-operative treatment. This study excluded any 
subjects who had prior botulinum toxin for plantar fasciitis. This study examined the subjects’ 
response to either a 1mL injection of 100U of IBTA vs. a saline placebo injection after 6 &12 
months.2 The principal investigator, the neurologist giving the injections, and all study patients 
were blinded from what substance was injected.2 Only the independent observer knew which 
study patients received IBTA and which patients received placebo.2 There were 0% loss to 
follow up at the conclusion of the research. The researchers used continuous data, which is 
provided in Table 2. The results of this study show that IBTA provided significant relief of pain 
due to plantar fasciitis compared with normal saline injection. Using a mean change from 
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baseline, examiners found that there were significant changes from baseline when comparing 
IBTA injection to saline placebo using a P< 0.05 as being statistically significant.    
Table 2: Post-injection Demographics between the Placebo and IBTA Groups.2
Post injection 
Demographics
Placebo IBTA P-Value
VAS at 6 months, 
mean (range)
7.9/10 (6-9) 3.6/10 (0-8) 0.01
Diaz-Llopis et. al., conducted a randomized, placebo controlled trial comparing 56 
subjects who presented with a diagnosis of plantar fasciitis. The authors reported a mean age of 
51.5 in the BTX-A group and 56.4 in the CS group respectively.5 This study included subjects 
with a clinical diagnosis of plantar fasciitis based on presence of heel pain during first steps after 
a period of rest or pain exacerbated by walking or by standing for many hours.5 This study 
excluded those with heel pain due to other causes or painful disorders of the foot that could 
coexist with plantar fasciitis.5 This study examined the subjects’ response after 6 months 
following injection of either; 100U of botulinum toxin type A (BTX-A) which was diluted with 
1mL of normal saline and 70U were injected or 2mL of betamethasone 6mg/mL plus 0.5 mL of 
1% mepivacaine (CS).5 Patients did not know which treatment they were to receive and the 
medication was prepared out of sight of the specialist performing the injection.5 However, they 
could not describe this as a true double-blind study as the injection volumes of the two 
treatments were different and the specialist could therefore guess which one was being given.5 
There were 0% loss to follow up at the conclusion of the research. The researchers used 
continuous data, which is provided in Table 3. The results of this study show that BTX-A 
provided significant relief of pain due to plantar fasciitis compared with the corticosteroid 
injection. Using a mean change from baseline, examiners found that there were significant 
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changes from baseline when comparing BTX-A injection to CS injection using a P< 0.05 as 
being statistically significant.    
Table 3: Difference in foot health status questionnaire scores between baseline, 1 month and 6 
months after treatment with BTX-A.3
FHSQ-pain At 1 month Change 
(FHSQ 1 
month-
baseline)
At 6 month Change 
(FHSQ 6 
month- 1 
month)
P-value
Mean (SD) 63.30 (21.90) 34.24 (21.10) 75.71 (24.14) 19.10 (24.76) P<0.001
Elizondo-Rodriguez et.al., conducted a randomized, double blinded, placebo controlled 
trial comparing 40 subjects who presented with a diagnosis of plantar fasciitis. The authors 
reported a mean age of 41.6 in the BTX-A group and 44.5 in the CS group respectively.6 This 
study included subjects who were skeletally mature with heel pain at the insertion of the plantar 
fascia or anteromedial tuberosity of the calcaneus; failure of conservative treatment for 3 months,
which consisted of pads in ordinary shoe and NSAIDs.5 This study excluded those who received 
previous injections, associated pathologies or a history of infection at the injection site in the 
previous 3 months.5 This study examined the subjects’ response to 100U of BTX-A which was 
injected into each muscle belly vs. a combination of 2% lidocaine and 8mg of dexamethasone 
(CS) injected into the medial aspect of the plantar surface after 6 months.5 The patients were 
randomly divided into 2 groups using a randomizing software program. The evaluation of the 
subjects’ response to treatment were made by a blinded investigator who was unaware of the 
patient group assignments.5 There were 10% loss to follow up at the conclusion of the research. 
The researchers used continuous data, which is provided in Table 4. The results of this study 
show that BTX-A provided significant relief of pain due to plantar fasciitis compared with the 
corticosteroid injection. Using a mean change from baseline, examiners found that there were 
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significant changes from baseline when comparing BTX-A injection to CS injection using a P< 
0.05 as being statistically significant.   
Table 4: Comparison between Groups Evaluating Visual Analogue Scale (VAS).5
Group A 
(BTX-A): 
Value
Group A 
(BTX-A): SD
Group B 
(CS): Value
Group B 
(CS): SD
P-value
Initial 7.1 1.75 7.7 1.32 Ns
Final 1.1 1.50 3.8 1.15 0.0005
Infections and other risks are associated with the interventions employed in these studies. 
Cases of rupture of the plantar fascia have been reported after corticosteroid injection.3,7 
However, none of the reviewed studies reported any drug related adverse effects or safety 
concerns. 
DISCUSSION:
This evidence based systematic review focused on the use of botulinum toxin injections 
being utilized to treat the symptoms of plantar fasciitis in those over the age of 18 years old. The 
etiology and pathogenesis of plantar fasciitis are still not fully understood.6 Although some 
authors consider the disorder to be the result of excessive tension in the fascia, producing 
microscopic tears which lead to a subsequent inflammatory repair process, many others have 
demonstrated degenerative changes, though without finding signs of inflammation.6 Entrapment 
of the first branch of the lateral plantar nerve has also been cited as a possible cause of heel pain.6
Regardless if a consensus regarding the pathogenesis of this disorder has not been reached 
throughout the industry, the fact still remains that patients seek treatment for their symptoms and 
require a therapy that will alleviate their discomfort even if it may be temporary. This uncertainty
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in having a widely accepted therapeutic intervention for plantar fasciitis mandates the need for 
further research into this topic. 
Throughout researching this topic, there were a few study limitations that could have 
impacted this review. A limitation that was apparent early on was the fact that many plantar 
fasciitis studies focused on surgical management. This significant narrowed the available studies 
to choose from. Another limitation was the fact that many of the studies had a small sample 
sizes. Therefore, finding studies that met the minimum requirements of statistical significance 
became challenging but was not overall impossible. If larger sample sizes could be utilized, the 
statistics would provide more evidence for the efficacy of the proposed treatment because the 
results could signify the true difference in efficacy and minimize the impact of confounding 
variables.  
CONCLUSION: 
The evidence presented in this systematic review shows that injections of botulinum toxin
have a positive effect on subjective pain scores after a period of six months. Within this period of
six months, patients were prescribed a formalized physical therapy program for a minimum of 
six weeks. Patients are encouraged to continue the modalities taught in these six week programs 
after the conclusion of the six weeks. The program involved active and passive stretching of the 
plantar fascia, great and lesser toe flexors, and Achilles tendons with and without resistance.2 
Other modalities that are regularly prescribed for physical therapy include ultrasound, massage, 
moist heat and cryotherapy.2 The physical therapy programs were employed regardless of the 
intervention utilized in the study. Therefore, physical therapy should always be integrated into 
the treatment plan to maximize the recovery of the patient’s symptoms. 
Fry, Botox for Plantar Fasciits 11
Only a few studies exist showing the therapeutic benefit of botulinum toxin injections for 
plantar fasciitis exist. Therefore, the efficacy of botulinum toxin in the treatment of plantar 
fasciitis is apparent but more research is needed with larger sample sizes to solidify the 
hypothesis that botulinum toxin injection should be an accepted treatment option across the 
industry. 
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